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report
Chemoradiation and the Role of
Adjuvant Chemotherapy in Lymph
Nodal–Metastatic Cervical Cancer
abstract
Purpose To report the long-term outcome in lymph nodal–metastatic cervical squamous cell cancer after
chemoradiation followed by adjuvant chemotherapy.
Patients and Methods Between 2010 and 2013, five patients were diagnosed with advanced cervical
cancer with clinically involved para-aortic lymph nodes (ie, International Federation of Gynecology and
Obstetrics stage IVB). These patients were treated with concurrent chemoradiation therapy followed by
adjuvant chemotherapy. Concurrent chemoradiation consisted of cisplatin given once per week con-
comitantly with extended-field radiation therapy followed by high-dose-rate brachytherapy. Adjuvant
chemotherapy comprised four courses of carboplatin and paclitaxel given every three weeks. The primary
outcomes were local and distant failures.
Results Noneof the patients had local recurrenceor distal failure after aminimum follow-up timeof 3 years.
Conclusion Adjuvant chemotherapy after chemoradiation has a probable role in the management of lymph
nodal–metastatic cervical cancer.
J Glob Oncol 00. © 2017 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Cervical cancer is an ominous disease when it
presents in locally advanced stages. To date, the
standard of care for locally advanced disease is
pelvic radiotherapywithconcurrentcisplatin-based
chemotherapy. However, distant failure remains a
major problem that leads to compromised overall
survival.1 To address this problem, a multinational
randomized trial was conducted in 2002,2 inwhich
patients received two cycles of adjuvant gemcita-
bine and cisplatin after completion of definitive
chemoradiation therapy. This treatment led to a
10% improvement in 3-year progression-free
survival. After this, no other trial was conducted
to explore improvements in overall survival.
At our university hospital, we treated two patients
in 2010, two in 2012, and one in 2013 with four
cycles of adjuvant carboplatin (area under the
curve [AUC] 5) and paclitaxel (175 mg/m2) after
completion of chemoradiation therapy. Two of
these patients have completed 5 years of follow-
up, two have completed 4 years of follow-up, and
onepatienthascompleted3yearsof follow-up.We
present a short report of five patients who had




A 45-year-old woman presented with locally
advanced squamous cell carcinoma of the cer-
vix. The staging positron emission tomogra-
phy (PET)/computed tomography (CT) scan
revealed a 6 3 8 cm metabolically active cer-
vical mass with pelvic and para-aortic lymph
nodes that measured more than 1 cm. She
received concurrent cisplatin (40mg/m2/week)
and extended-field radiation therapy to the
pelvis and the para-aortic region after three-
dimensional CT-based planning. The pelvis and
para-aortic field received a dose of 45 Gy at 1.8
Gy/day, followed by a boost to 50.4 Gy to the
para-aortic and pelvic side wall nodes. She then
received three high-dose-rate (HDR) brachy-
therapy fractions, and an 8-Gy dose was pre-
scribed at point A in each fraction. After
completion of chemoradiation therapy and bra-
chytherapy, she received four cycles of carbopla-
tin and paclitaxel. She completed the whole
treatment in June 2010. The follow-up PET/CT
scan revealed metabolic complete response at
nodal and primary sites. She is free of any disease
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Patient Case 2
In a 43-year-old woman who presented after par-
tial hysterectomy (performed elsewhere), histopa-
thologywasconsistentwithcervical squamouscell
carcinoma, and resection margins were reported
to be positive. Her postoperative CT scan revealed
4-cm residual disease at the vaginal vault with left
parametrial invasion, multiple pelvic nodes, and a
2-cm enhancing left para-aortic node; also, she
had a left pelvic kidney. The treatment planwas as
follows: radiation therapy to the pelvis and para-
aortic field with a concurrent cisplatin dose of
40 mg/m2 once per week. Because of previous
partial hysterectomy, brachytherapy could not be
performed, so she received additional boost dose
to the para-aortic nodes to a total dose of 50.4 Gy
and to thepelvicmass to a total doseof 63Gyat1.8
Gy/day. After completion of chemoradiation ther-
apy, the patient received four cycles of adjuvant
carboplatin and paclitaxel until June 2010. At 5
years of follow-up, she is free of any disease on
clinical examination and by CT scan performed in
March 2015. Her last follow-up visit was on April
27, 2016.
Patient Case 3
This 48-year-old multiparous woman presented
with biopsy-proven squamous cell carcinoma of
the cervix. The staging CT scan revealed a large
cervical mass as well as pelvic side wall and para-
aortic lymphadenopathy. Para-aortic nodes were
measured asmore than 2 cm in the short axis. The
planned treatment was chemoradiation therapy to
the pelvis and para-aortic nodes to a total dose of
45 Gy at 1.8 Gy/fraction with cisplatin 40 mg/m2
once per week followed by HDR brachytherapy
to a total dose of 24Gy in three fractions to point A.
After completion of chemoradiation therapy, the
patient received four cycles of carboplatin and
paclitaxel chemotherapy until January 2012.
She was free of disease at the last follow-up visit
on September 9, 2016.
Patient Case 4
This 54-year-old woman presented with biopsy-
proven squamous cell carcinoma of the cervix; on
examination under anesthesia, the disease was
staged as IIIB. However, on a staging CT scan of
the chest, abdomen, and pelvis, there were mul-
tiple para-aortic nodes that were more than 2 cm
each just below the left renal hilum. The disease
ultimately was staged as IVB squamous cell car-
cinoma. The planned treatment was extended-
field radiation therapywithconcurrentchemother-
apy followed by HDR brachytherapy, then four
cycles of chemotherapy with carboplatin and pac-
litaxel. The patient completed treatment in Octo-
ber 2012. She was in remission at the last follow-
up on October 26, 2016.
Patient Case 5
This 62-year-old multiparous woman presented
with cervical biopsy–proven, nonkeratinizing
squamous cell carcinoma. Examination under
anesthesia revealed a 6 3 6 cm cervical mass
fixed to the right pelvic side wall, and a staging
CT scan showed a 3.5 3 7 cm nodal mass just
superior to aortic bifurcation on the right side. The
patient received 45Gyper 25 fractions of external-
beam radiation therapy to the pelvis and para-
aortic field with concurrent cisplatin chemother-
apy. In last three cycles of chemotherapy, thedose
of cisplatin had to be reduced to 30/mg/m2 be-
cause of grade II hematologic toxicity. This radi-
ation was followed by a boost to the right para-
aortic node up to 60 Gy and HDR brachytherapy
at a dose of three fractions of 8 Gy each to point A.
After chemoradiation therapy, thepatient received
four cycles of carboplatin and paclitaxel chemo-
therapy until June 2013. On the PET/CT scan
and a clinical examination at the last follow-up
in June 2016, she was free of any disease.
Radiation Therapy Technique
CT simulation was performed with intravenous
contrast in all patients. For immobilization and
reproducibility of set-up, an alpha cradle vac-
lockwasused inCTsimulation.Thesuperiorborder
of the fieldwasplacedat the topof theD12vertebral
body, and the inferiorborderwas3cminferior to the
caudal-most extent of the disease in the vagina. A
normal saline–soaked gauze piecewas put into the
vagina for a negative contrast on imaging. A radio-
opaque marker was placed at the vaginal introitus,
and a plastic tube was placed in the anal canal for
facilitation of visualization of organs at risk. Lateral
borders were placed 2 cm away from the pelvic
bony margin and 1 cm away from the para-aortic
volumeof the nodes, andmultileaf collimatorswere
used to shield normal tissue. Extended pelvis and
para-aortic fieldswere treatedeachdaywithantero-
posterior (AP), postero-anterior (PA), and right and
left lateral fields with 18 MV of photon energy. The
radiation planning was performed on Aria 10 plan-
ning software (Varian, Palo Alto, CA).
Complete bloodcounts and serumcreatininewere
checked once per week. All of the fields were
treated each day for 5 days per week. Treatment-
verification portal films were taken once per week
for accuracy of treatment fields.
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In the last week of external-beam radiotherapy,
first fraction of HDR brachytherapy was insti-
tuted with tandem and ovoid applicators. The
brachytherapy procedure was performed un-
der general anesthesia, and careful gauze-piece
packing was performed to displace the rectum
and bladder away from the applicators. The
HDR brachytherapy dose was prescribed at
point A according to International Commission
on Radiation Units and Measurements re-
port 38.
RESULTS AND DISCUSSION
Advanced cervical cancer is a virulent disease,
and the 5-year disease-free survival rate is dismal.
One attempt was made to improve overall survival
in locally advanced cervical cancer in a random-
ized trial that compared adjuvant cisplatin and
gemcitabine versus no additional chemotherapy.
This trial showeda10%improvement in the3-year
progression-free survival, but improvement was at
the cost of slightly increased toxicity seen in the
group that received gemcitabine and cisplatin.3
In a retrospective analysis, Kim et al4 failed to
show a significant difference in survival in patients
who received adjuvant chemotherapy in locally
advanced cervical cancer. In a phase II trial,
Chung et al5 treated patients with extended-field
radiotherapy, concurrent chemotherapy, and bra-
chytherapy followed by two cycles of adjuvant
cisplatin and fluorouracil and demonstrated that
this treatment regimen was feasible. However, we
used extended-field chemoradiation therapy,
HDR brachytherapy, and four cycles of adjuvant
carboplatin and paclitaxel chemotherapy for our
patients; toxicitywasacceptableandmanageable.
Verghese et al,6 in a phase II trial, used cisplatin
and paclitaxel concurrent with radiotherapy in an
attempt to improve the outcome for locally ad-
vanced cervical cancer in Indian women. The trial
failed to show any improvement in response com-
paredwith cisplatin alone, and toxicity was greater
in the combination-chemotherapy arm. At our
center, we used single-agent cisplatin concurrent
with radiotherapy followed by the combination of
carboplatin andpaclitaxel as adjuvant chemother-
apy, and toxicity was less than grade 3 and
manageable.
To date, no randomized trial is available to assess
the impact of carboplatin and paclitaxel as adju-
vant combination chemotherapy after chemora-
diation therapy in locally advanceddisease. A review
by Tangjitgamol et al1 found evidence to use adju-
vant chemotherapy after chemoradiation therapy for
locally advanced cervical cancer. Recently,
such a trial was initiated in Australia7 in which
patients with International Federation of Gy-
necology and Obstetrics (FIGO) stages IB1 to
IVA cervical cancer were randomly assigned to
receive four cycles of adjuvant carboplatin and
paclitaxel or to receive no additional chemo-
therapy after completion of chemoradiation
therapy. However, we opted to offer this treat-
ment to patients who had FIGO stage IVB
disease (para-aortic lymphadenopathy). Pa-
tient case 2 had residual 4-cm cervical cancer
at the vaginal vault, and she received salvage
chemoradiation therapy to the pelvis and para-
aortic nodal region. To the pelvic mass, she
received a total of 63 Gy at 1.8 Gy/fraction after
three-dimensional conformal radiotherapy.
Also, she completed her 5 years of follow-up
and is free of any recurrent disease. There is
evidence of adequate local control with radical
radiotherapy of residual disease after inade-
quate hysterectomy for cervical cancer.8-10
Petrić Miše et al11 and Jelavić et al12 reported
encouraging results of four adjuvant cycles of
cisplatin and ifosfamide chemotherapy after
completion of concurrent chemoradiotherapy
in an attempt to improve distant-relapse–free
survival. In a randomized trial, Wong et al13
showed improvement in overall survival after
administration of adjuvant chemotherapy with
epirubicin at 90 mg/m2 compared with pelvic
radiotherapy and no additional chemotherapy.
This is a unique report of treatment for patientswith
stage IVB disease (para-aortic lymphadenopathy).
In the modern era of oncology, oncologists come
across patients with advanced-stage disease not
infrequently, and the treating oncologist, patients,
and families often fail to understand the prognosis
and goals of treatment, which can lead to a poor
outcome of treatment.14 Should the FIGO stage
IVB disease be segregated into two groups,
patients with widespread distant metastases
and those with para-aortic nodes only. Should
the patients with para-aortic disease only have
a better prognosis, provided they were treated
aggressively. This questionmay get its answer in
the near future. We hope that the results of the
OUTBACKtrial (ClinicalTrials.govNo.NCT01414608)
will be able to resolve the question of whether to use
adjuvant chemotherapy administration in locoregion-
ally advanced cervical cancer.7
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